Betta Pharmaceuticals Co., Ltd. (SHE:300558)
China · Delayed Price · Currency is CNY 46.52
+6.42 (16.01%)
Nov 2, 2026, 3:04 PM CST
Betta Pharmaceuticals Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
| 19,693 | 19,644 | 22,569 | 21,573 | 20,525 | 33,154 | |
Market Cap Growth | -17.72% | -12.96% | 4.62% | 5.11% | -38.09% | -25.26% |
Enterprise Value | 21,471 | 21,688 | 24,170 | 23,045 | 20,899 | 31,905 |
Last Close Price | 46.52 | 46.55 | 53.59 | 51.00 | 48.67 | 78.42 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
PE Ratio | 73.57 | 64.34 | 56.06 | 61.99 | 141.14 | 86.55 |
Forward PE | 28.02 | 26.59 | 29.63 | 42.25 | 65.91 | 49.20 |
PS Ratio | 5.18 | 5.44 | 7.80 | 8.78 | 8.64 | 14.76 |
PB Ratio | 3.01 | 2.95 | 3.98 | 4.03 | 4.14 | 7.08 |
P/TBV Ratio | 5.44 | 5.49 | 9.47 | 7.45 | 6.38 | 11.18 |
P/FCF Ratio | 63.02 | 66.69 | 270.04 | - | - | - |
P/OCF Ratio | 22.83 | 21.56 | 24.77 | 23.60 | 66.91 | 62.96 |
PEG Ratio | - | 0.96 | 0.99 | 3.08 | 3.08 | 3.08 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 5.65 | 6.01 | 8.36 | 9.38 | 8.79 | 14.21 |
EV/EBITDA Ratio | 16.86 | 19.93 | 28.60 | 39.86 | 46.08 | 61.61 |
EV/EBIT Ratio | 36.50 | 40.13 | 50.68 | 82.34 | 100.98 | 91.48 |
EV/FCF Ratio | 68.71 | 73.62 | 289.20 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.38 | 0.37 | 0.42 | 0.45 | 0.21 | 0.00 |
Debt / EBITDA Ratio | 1.94 | 2.26 | 2.82 | 4.17 | 2.27 | 0.02 |
Debt / FCF Ratio | 7.92 | 8.36 | 28.67 | - | - | - |
Net Debt / Equity Ratio | 0.27 | 0.30 | 0.32 | 0.31 | 0.06 | -0.21 |
Net Debt / EBITDA Ratio | 1.39 | 1.81 | 2.13 | 2.90 | 0.70 | -1.90 |
Net Debt / FCF Ratio | 5.66 | 6.68 | 21.51 | -9.23 | -0.45 | 4.24 |
Asset Turnover | 0.38 | 0.36 | 0.31 | 0.29 | 0.34 | 0.39 |
Inventory Turnover | 2.48 | 2.20 | 1.74 | 1.16 | 0.81 | 0.72 |
Quick Ratio | 0.66 | 0.48 | 0.38 | 0.58 | 0.59 | 1.36 |
Current Ratio | 1.00 | 0.82 | 0.66 | 0.85 | 0.82 | 1.86 |
Return on Equity (ROE) | 4.02% | 4.64% | 7.03% | 6.47% | 2.59% | 8.60% |
Return on Assets (ROA) | 3.69% | 3.39% | 3.23% | 2.05% | 1.82% | 3.79% |
Return on Invested Capital (ROIC) | 4.33% | 4.64% | 6.46% | 4.55% | 4.61% | 10.75% |
Return on Capital Employed (ROCE) | 7.20% | 6.20% | 6.40% | 3.80% | 3.60% | 6.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Earnings Yield | 1.36% | 1.55% | 1.78% | 1.61% | 0.71% | 1.16% |
FCF Yield | 1.59% | 1.50% | 0.37% | -0.84% | -3.43% | -0.70% |
Dividend Yield | 0.32% | 0.32% | 0.37% | 0.33% | 0.14% | 0.31% |
Payout Ratio | 47.68% | 49.38% | 37.48% | 31.69% | 95.94% | 35.93% |
Buyback Yield / Dilution | -0.18% | 0.26% | -0.01% | -0.72% | 0.02% | -2.32% |
Total Shareholder Return | 0.14% | 0.58% | 0.36% | -0.39% | 0.16% | -2.00% |